Navigation Links
Combination antibiotics effective against chlamydia-induced arthritis
Date:4/28/2010

Tampa, FL (April 29, 2010) -- Combination antibiotics effectively treat Chlamydia-induced reactive arthritis a major step toward management, and possibly cure, of this disease, a federal multicenter clinical trial led by the University of South Florida College of Medicine found.

The trial, sponsored by the National Institute of Musculoskeletal and Skin Diseases, is reported in the May 2010 issue of Arthritis and Rheumatism, a journal of the American College of Rheumatology. The paper is accompanied by an editorial in which an internationally-recognized research group from Germany calls the study results "impressive."

"Our findings lend hope that eradication of this persistent infection is attainable and a possible cure exists," said John D. Carter, MD, associate professor of medicine in the USF Health Division of Rheumatology and lead author of the study.

Reactive arthritis (ReA), also known as Reiter's syndrome, is an autoimmune disorder that develops in response to an infection elsewhere in the body. This type of arthritis is most commonly caused by the bacteria Chlamydia trachomatis, usually acquired through sexual contact, or Chlamydia pneumoniae, which can trigger respiratory infection. The organism migrates from the initial site of infection typically the genitourinary or respiratory tract through the blood to the joint tissue. Pain and swelling in the sacroiliac joints, knees, ankles and feet are common.

Data suggests that the incidence of ReA rivals or even surpasses that of rheumatoid arthritis (an estimated 125,000 new cases a year), Dr. Carter said, but less is known about ReA, which is often misdiagnosed.

Most people recover fully from the initial flare-up of arthritis symptoms, but about 20 percent of those with ReA experience long-lasting symptoms. Studies have shown that the presence of metabolically-active Chlamydia in the joints of these individuals causes inflammation even years after the initial infection. That begged the question: could antibiotics treat Chlamydia-induced ReA? Previous clinical trials with single antibiotics were negative or failed to demonstrate any definitive effect.

A nine-month study by Dr. Carter and colleagues, published in 2004 in the Journal of Rheumatology, was the first to compare combination antibiotic therapy (doxycycline and rifampin) with monotherapy (doxycycline only). It showed a dramatic response to the combination in patients with Chlamydia-induced arthritis.

Based on these promising early results, the USF-led research team devised a new prolonged course of combination antibiotic treatment, which attacked two different pathways allowing Chlamydia infection to persist in the joints.

In the latest double-blind, placebo-controlled multicenter trial, 42 patients were randomly assigned to one of three treatment groups -- rifampin plus doxycycline, rifampin plus azithromycin, or placebo. All the patients tested positive for Chlamydia trachomatis or Chlamydia pneumoniae. They received combination antibiotics or placebo for six months and were followed for three months post-treatment.

Patients treated with the combination antibiotics improved significantly more in measures of the swelling and tenderness of joints and symptom assessment. In fact, the researchers report, 22 percent of patients receiving combination antibiotics experienced complete remission of ReA, while none in the placebo group did. Significantly more patients receiving combination antibiotics tested negative for Chlamydia bacteria in their blood or joint tissue following treatment. Adverse side effects, mostly gastrointestinal, were mild.

In an editorial appearing in the same issue as the USF-led study, Dr. Markus Rihl of Hannover Medical School in Germany writes, "the positive results using combination antibiotics are very promising to open a new way of treatment not only for Chlamydia-induced ReA but also for Chlamydia-induced spondylarthritis."

The editorial states the approach warrants further study to elucidate which antibiotic combination, dosing, and duration of therapy is most effective while minimizing the risk of bacterial resistance.


'/>"/>

Contact: Anne DeLotto Baier
abaier@health.usf.edu
813-974-3300
University of South Florida Health
Source:Eurekalert  

Related medicine news :

1. New Drugs, New Combinations Fight Breast Cancer
2. Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling
3. Multiple myeloma patients experience high response rate with new 3-drug combination
4. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
5. Combination therapy more effective for enlarged prostate
6. Combination Treatment May Help Depressed Alcoholics
7. Researchers find new chemotherapy combination shows promise in endometrial cancer
8. Leeza Gibbons and ZERONA Equals a Winning Combination
9. Disinfectant Misuse Might Help Germs Resist Antibiotics
10. Giant Eagle Pharmacy Free Antibiotics Program Surpasses $3 Million in Free Prescriptions
11. Poll: Hypothetical anthrax attack and antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combination antibiotics effective against chlamydia-induced arthritis
(Date:1/16/2017)... ... 16, 2017 , ... NexTec Group has been selected as a member of ... their accomplishments in the field of midmarket financial software. , Members of the VAR ... Selection is not based on revenue and those firms chosen represent a wide range ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... "On Tour ... slideshow with complete customization and ease," said Christina Austin - CEO of Pixel Film ... so that users can edit the style and animation of their slideshows. Place each ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy ... expanding line of activated charcoal products. With more and more people opting to ... products according to how they cater to specific needs. , Moody Zook focused ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in ... is expertly designed to meet the educational needs of European oncology clinicians and researchers ... Dr. Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized ...
(Date:1/13/2017)... ... January 13, 2017 , ... An inventor from Virginia Beach, ... brown belt in order to diversify my outfits, so he decided to design something ... THE T.O.O.B. enhances the appearance of a belt to allow for quick, easy changing ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Bill is an internationally experienced medical device industry executive who ... global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and ... and building successful businesses in the sector and has worked in ... North America . ... Educated at the University of Edinburgh (Dental Surgery), ...
(Date:1/16/2017)... Analytics 4 Life (A4L), a machine intelligence company developing ... @ Toronto , one of Johnson ... in the space, A4L has access to a rich ... JLABS @ Toronto ... flexible environment for start-up companies pursuing new technologies and ...
(Date:1/16/2017)... NASHVILLE, Tenn. , Jan. 16, 2017  Cumberland ... addition of Kenneth J. Krogulski , CFA to ... Chief Executive Officer of Berkshire Asset Management LLC ... Berkshire, a 30-year-old independent SEC registered investment advisory firm ... Krogulski has over 37 years, experience in security analysis ...
Breaking Medicine Technology: